Eli Lilly and Company $LLY Shares Sold by Cypress Capital Group

Cypress Capital Group decreased its position in Eli Lilly and Company (NYSE:LLY) by 1.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,412 shares of the company’s stock after selling 673 shares during the quarter. Eli Lilly and Company accounts for about 4.7% of Cypress Capital Group’s holdings, making the stock its 2nd biggest holding. Cypress Capital Group’s holdings in Eli Lilly and Company were worth $39,227,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Laurel Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Norges Bank purchased a new stake in Eli Lilly and Company during the 2nd quarter worth about $8,827,714,000. Jennison Associates LLC boosted its position in shares of Eli Lilly and Company by 4.3% during the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after acquiring an additional 226,620 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after acquiring an additional 103,119 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.0%

Shares of NYSE:LLY opened at $1,023.81 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market cap of $967.89 billion, a P/E ratio of 50.09, a P/E/G ratio of 0.77 and a beta of 0.35. The firm has a fifty day moving average price of $1,057.27 and a 200 day moving average price of $887.02.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the company earned $1.18 earnings per share. The business’s revenue was up 53.9% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 29.35%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly struck a potential $1.93 billion deal with Repertoire Immune Medicines to develop autoimmune therapies, expanding its pipeline in high‑value immune diseases and adding near‑ and mid‑term development optionality. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: Lilly agreed to a collaboration/option deal with gene‑editing firm Seamless (up to $1.12B) targeting hearing‑loss programs—diversifies R&D and signals commitment to next‑gen modalities. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: President Trump said Lilly plans to build six U.S. manufacturing plants — a boost for supply-chain resilience, potential capacity for GLP‑1 and other biologics, and a politically favorable narrative. Trump says Eli Lilly to build six US plants
• Positive Sentiment: Analysts/coverage point to strong Q4 fundamentals, oncology pipeline momentum and an AI partnership (Nvidia) positioning Lilly for R&D acceleration—supportive for earnings and longer‑term growth expectations. Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation
• Positive Sentiment: A Seeking Alpha take argues Lilly’s obesity‑pricing tradeoffs (access vs. price) are a net positive, supporting adoption and sales momentum for GLP‑1/obesity launches. Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive
• Neutral Sentiment: Wall Street expects continued earnings strength and a likely beat in the upcoming report based on Lilly’s recent surprise history—this can support sentiment if results meet/beat. Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Coverage pieces and bullish theses reiterate Lilly’s secular GLP‑1/oncology story but note valuation is rich—supports conviction but increases sensitivity to execution. Eli Lilly and Company (LLY): A Bull Case Theory
• Negative Sentiment: Competitive pressure: Novo Nordisk is outspending Lilly on U.S. GLP‑1 advertising by a wide margin, which could pressure market share and marketing efficiency. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Policy risk: Medicare’s expanded negotiation list includes Lilly’s Verzenio, introducing potential pricing pressure for certain oncology revenues if negotiations lead to cuts. Medicare is about to start negotiating the prices of medications administered by doctors
• Negative Sentiment: Market reaction: some coverage notes shares dipped after the gene‑editing tie‑up, illustrating sensitivity to deal economics and investor focus on near‑term margins versus long‑term optionality. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership

Analyst Ratings Changes

A number of brokerages recently issued reports on LLY. Wolfe Research upped their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Leerink Partners set a $1,234.00 target price on shares of Eli Lilly and Company in a research report on Monday, January 5th. Guggenheim reduced their price target on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Finally, Bank of America decreased their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Buy” and an average target price of $1,173.91.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.